AGIOS PHARMACEUTICALS, INC. Operating Lease Liability
AGIOS PHARMACEUTICALS, INC. (AGIO) had Operating Lease Liability of $31.17 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-07-30
- 2026-06-30: Operating Lease, Liability $31.17M.
- 2026-03-31: Operating Lease, Liability $35.74M.
- 2025-12-31: Operating Lease, Liability $40.21M.
- 2025-09-30: Operating Lease, Liability $44.52M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $31.17M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $35.74M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $40.21M 10-K · filed 2026-02-12 |
| 2025-09-30 | $44.52M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $48.76M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $52.94M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $56.99M 10-K · filed 2025-02-13 |
| 2024-09-30 | $60.83M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $64.62M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $68.35M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $72.00M 10-K · filed 2024-02-15 |
| 2023-09-30 | $75.50M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $78.95M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $82.34M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $85.66M 10-K · filed 2023-02-23 |
| 2022-09-30 | $88.84M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $91.00M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $94.08M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $96.49M 10-K · filed 2022-02-24 |
| 2021-09-30 | $98.72M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $100.90M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $103.04M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $104.55M 10-K · filed 2021-02-25 |
| 2020-09-30 | $106.57M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $108.55M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $110.48M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $112.72M 10-K · filed 2020-02-19 |
| 2019-09-30 | $115.39M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $116.47M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $75.13M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |